Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)

First published 24/10/2025

Last updated 01/10/2026

EU PAS number:

EUPAS1000000776

Study

Ongoing

Download as PDF

Documents

Study protocol

No information provided.

Study results

No information provided.

Study report

No information provided.

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

No information provided.

Enzalutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) in Metastatic Hormone Sensitive Prostate Cancer (mHSPC): A Non-Interventional Center-based Chart Review in Europe (ENHANCE)

Secondary tabs

Share this page